Tag - IDRA

Developments

Idera Pharma reports positive initial Phase 2 data of tilsotolimod in colorectal cancer

Idera Pharma (NASDAQ:IDRA) reported positive preliminary data from its Phase 2 trial of tilsotolimod, in combination with Opdivo and Yervoy, in immunotherapy-naive micro-satellite stable colorectal cancer (MSS-CRC)...

June 4, 2020

Developments

Idera Pharma presents positive Phase 1 data of tilsotolimod for solid tumors

Idera Pharma (NASDAQ:IDRA) presented results of its Phase 1 trial of tilsotolimod as monotherapy in patients with various refractory solid tumors. Tilsotolimod is a toll-like receptor 9 agonist that activates cancer...

April 3, 2019

Tag - IDRA

Idera Pharma reports positive initial Phase 2 data of tilsotolimod in colorectal cancer

Idera Pharma presents positive Phase 1 data of tilsotolimod for solid tumors

General

More